Retatrutide represents the next generation of multi-receptor agonists, often referred to in clinical circles as a triple-G hormone because it targets the GLP-1, GIP, and glucagon receptors simultaneously. This dual-incretin plus glucagon mechanism sets it apart from older single or dual-action peptides by potentially offering greater weight reduction and metabolic…